Lyell Immunopharma (NASDAQ:LYEL) CEO Lynn Seely Sells 7,455 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely sold 7,455 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total transaction of $174,372.45. Following the completion of the sale, the chief executive officer owned 74,266 shares in the company, valued at $1,737,081.74. This represents a 9.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Lynn Seely also recently made the following trade(s):

• On Tuesday, February 10th, Lynn Seely sold 438 shares of Lyell Immunopharma stock. The stock was sold at an average price of $23.12, for a total value of $10,126.56.

Lyell Immunopharma Price Performance

NASDAQ LYEL opened at $25.38 on Friday. The company has a fifty day moving average price of $27.98 and a 200-day moving average price of $19.64. Lyell Immunopharma, Inc. has a 1 year low of $7.65 and a 1 year high of $45.00. The firm has a market cap of $539.07 million, a price-to-earnings ratio of -1.10 and a beta of -0.14.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.81) by $0.68. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.01 million. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. On average, research analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Key Headlines Impacting Lyell Immunopharma

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Lyell dosed the first patient in PiNACLE, a Phase 3 head?to?head CAR?T trial comparing rondecabtagene autoleucel (ronde?cel / LYL314) to liso?cel or axi?cel in 2L relapsed/refractory large B?cell lymphoma — a meaningful clinical and regulatory de?risking step if the program advances. PiNACLE Phase 3 dosing
• Neutral Sentiment: Research and institutional positioning — the stock carries a mixed analyst profile (HC Wainwright upgraded LYEL to Buy and raised its PT previously) and significant institutional ownership (~66%), which can amplify moves but doesn’t change near?term binary clinical risk. MarketBeat LYEL profile
• Negative Sentiment: Multiple insider sales this week — CEO Lynn Seely, COO Stephen Hill, insider Gary K. Lee and VP Veronica Sanchez Bulis reported sales on Feb. 10–11 that reduced their holdings (including a CEO sale of 7,455 shares on Feb. 11). Large or clustered insider selling can weigh on sentiment even if for personal/diversification reasons. SEC filings: CEO 2/11 Form 4 Gary Lee 2/11 Form 4 COO 2/11 Form 4 CEO 2/10 Form 4

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. HC Wainwright upgraded shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $20.00 to $45.00 in a report on Tuesday, December 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Lyell Immunopharma currently has a consensus rating of “Hold” and an average price target of $45.00.

Institutional Trading of Lyell Immunopharma

Several institutional investors have recently made changes to their positions in the business. ARCH Venture Management LLC raised its stake in Lyell Immunopharma by 51.5% during the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock valued at $44,807,000 after purchasing an additional 938,438 shares in the last quarter. GSK plc acquired a new position in shares of Lyell Immunopharma during the fourth quarter worth $46,560,000. Vanguard Group Inc. increased its position in Lyell Immunopharma by 76.0% during the 3rd quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after buying an additional 336,378 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after purchasing an additional 443,614 shares in the last quarter. Finally, Foresite Capital Management V LLC lifted its stake in shares of Lyell Immunopharma by 17.3% during the third quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company’s stock worth $7,748,000 after buying an additional 70,426 shares during the period. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.